RIGL - Rigel Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Show:
Income Statement
Balance Sheet
Cash Flow

Income Statement

Annual
All numbers in thousands
Revenue12/31/201712/31/201612/31/201512/31/2014
Total Revenue-20,38328,8958,250
Cost of Revenue46,26963,44662,82567,696
Gross Profit-41,785-43,063-33,930-59,446
Operating Expenses
Research Development----
Selling General and Administrative-20,90817,81322,501
Non Recurring----
Others---9,302
Total Operating Expenses-84,35480,63899,499
Operating Income or Loss--63,971-51,743-91,249
Income from Continuing Operations
Total Other Income/Expenses Net--5,245279341
Earnings Before Interest and Taxes--63,971-51,743-91,249
Interest Expense----
Income Before Tax--69,216-51,464-90,908
Income Tax Expense----
Minority Interest----
Net Income From Continuing Ops--69,216-51,464-90,908
Non-recurring Events
Discontinued Operations----
Extraordinary Items----
Effect Of Accounting Changes----
Other Items----
Net Income
Net Income--69,216-51,464-90,908
Preferred Stock And Other Adjustments----
Net Income Applicable To Common Shares--69,216-51,464-90,908